Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.14% Nasdaq Down0.84%

Cleveland BioLabs, Inc. (CBLI)

-NasdaqCM
0.65 0.00(0.00%) 2:42PM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Cleveland BioLabs, Inc.
73 High Street
Buffalo, NY 14203
United States - Map
Phone: 716-849-6810
Fax: 716-849-6820
Website: http://www.cbiolabs.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:44

Business Summary 

Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the ChildrenÂ’s Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Cleveland BioLabs, Inc.

Key Executives 
 PayExercised
Dr. Yakov N. Kogan Ph.D., M.B.A., 41
Co-Founder, Chief Exec. Officer and Director
414.00K0.00
Dr. Michael Fonstein Ph.D., 55
Co-Founder
411.00K0.00
Dr. Andrei V. Gudkov Ph.D., D.Sci., 58
Co-Founder, Chief Scientific Officer and Director
222.00K0.00
Mr. C. Neil Lyons CPA, 57
Chief Financial Officer and Principal Accounting Officer
260.00K0.00
Dr. George R. Stark Ph.D., FRS,
Co-Founder
N/AN/A
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders